BPC-157 is one of the most searched and most discussed compounds in the research-peptide space. This article is an educational overview for the scientific and research community: what BPC-157 actually is, what preclinical studies have reported, where the research is heading in 2026, and how U.S. regulators currently classify it. Nothing here is medical advice, and BPC-157 is not an approved drug.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids (CAS 137525-51-0). Its sequence corresponds to a partial fragment of a protein originally identified in human gastric juice, which is why so much of the early laboratory interest focused on the digestive tract. In research settings it is handled as a stable, water-soluble lyophilized peptide and is studied strictly in vitro and in animal models.
The BPC-157 literature is almost entirely preclinical — cell cultures and rodent models. Across those studies, the most frequently reported themes are:
Important caveat for researchers: these findings come from laboratory and animal experiments. They describe observed effects and proposed mechanisms — they are not evidence of safety or benefit in humans.
Interest in BPC-157 has continued to grow, with new reviews consolidating the preclinical evidence and repeatedly calling for rigorous, controlled human studies. As of 2026, no completed human clinical trials establish efficacy or safety, and BPC-157 remains an experimental research compound. The honest state of the science is straightforward: promising signals in animal models, and a clear gap where properly designed human research would need to be.
BPC-157 is not FDA-approved for any use. In 2023 the FDA placed it in Category 2 of its interim 503A review — substances the agency flagged as potentially presenting significant safety risks for use in pharmacy compounding.
The picture became more nuanced in mid-2026. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 (with one abstention) to recommend adding BPC-157 (and KPV) to the 503A bulk drug substances list — a vote that went against FDA staff scientists, who had cited a "lack of evidence to support the effectiveness of BPC-157" and described the compound as not well-characterized. It is important to understand that this committee vote is a non-binding recommendation; the FDA itself makes the final decision, and the outcome was still pending after the meeting. We cover that meeting in detail in our FDA peptide compounding review.
The takeaway for researchers: the regulatory conversation is active and evolving, but BPC-157 today remains an unapproved compound studied strictly as a research chemical.
Reproducible research depends on knowing exactly what is in the vial. That is why every batch we supply is analyzed by third-party HPLC and ships with a Certificate of Analysis (COA) documenting identity and purity. If you are evaluating BPC-157 for a study, lot-level purity data is the difference between clean, citable results and uncontrolled variables. You can review our published certificates of analysis for reference.
We supply BPC-157 to the research community — HPLC-tested to 99% purity, with a certificate of analysis on every batch, shipped from the USA, strictly for in-vitro laboratory use:
View BPC-157 (research grade) Browse all research compounds
Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.